It has been previously demonstrated that DBI is present in endocrine pancreas and it is able to inhibit insulin release in isolated rat islets. Its mechanism of action has been investigated, demonstrating the possible involvement of cAMP and ATP-dependent K+ channels. DB133-50, a post-translational product of DBI, is also able to inhibit insulin release, but its action has not been characterized. In the present study, we have investigated the presence of DBI mRNA in pancreas, islets and cultured ß cells. The possible mechanism of action of DBI33-50 and the involvement of BZ/GABAA receptors has been studied
DBI mRNA is expressed in endocrine pancreas and its post-translational product DBI 33-50 inhibits insulin release / Borboni, P; Magnaterra, R; Porzio, O; Fusco, A; Sesti, G; Bertoli, A; Lauro, R; Marlier, L.. - In: ENDOCRINE. - ISSN 1355-008X. - 3:(1995), pp. 267-271.
DBI mRNA is expressed in endocrine pancreas and its post-translational product DBI 33-50 inhibits insulin release
Sesti GSupervision
;
1995
Abstract
It has been previously demonstrated that DBI is present in endocrine pancreas and it is able to inhibit insulin release in isolated rat islets. Its mechanism of action has been investigated, demonstrating the possible involvement of cAMP and ATP-dependent K+ channels. DB133-50, a post-translational product of DBI, is also able to inhibit insulin release, but its action has not been characterized. In the present study, we have investigated the presence of DBI mRNA in pancreas, islets and cultured ß cells. The possible mechanism of action of DBI33-50 and the involvement of BZ/GABAA receptors has been studiedI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
